# US 2012/0252011 A1 · Composition for treatment of pancreatic cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252011 A1
- Document ID: US20120252011A1
- Status: Published application
- Kind: A1
- Application number: 13/499,005
- Filed: 2010-09-13
- Published: 2012-10-04
- Earliest claimed: 2009-10-01
- Assignees: Tokyo Women's Medical University
- Inventors: Toru Furukawa
- Web page: https://patentgrep.com/patent/US20120252011A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/14: interfering nucleic acids [NA]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a composition for treating pancreatic cancer. The composition comprises a pharmaceutically effective amount of an antisense nucleic acid or siRNA that inhibits expression of at least one gene selected from the group consisting of SON gene, MCM5 gene, WDR5 gene, PBK gene and CENPA gene. The composition inhibits the expression of a specific gene to provide the effect of inhibiting the proliferation, survival and tumorigenicity of pancreatic cancer cells.

## Claims

### Claim 1

A composition for treatment of pancreatic cancer, which comprises a pharmaceutically effective amount of an antisense nucleic acid or siRNA inhibiting expression of at least one gene selected from the group consisting of SON gene, MCM5 gene, WDR5 gene, PBK gene and CENPA gene.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the sense strand of the siRNA inhibiting expression of the SON gene comprises the nucleotide sequence of SEQ ID NO: 1 or 3.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the sense strand of the siRNA inhibiting expression of the MCM5 gene comprises the nucleotide sequence of SEQ ID NO: 5.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the sense strand of the siRNA inhibiting expression of the WDR5 gene comprises the nucleotide sequence of SEQ ID NO: 7.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the sense strand of the siRNA inhibiting expression of the PBK gene comprises the nucleotide sequence of SEQ ID NO: 9.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the sense strand of the siRNA inhibiting expression of the CENPA gene comprises the nucleotide sequence of SEQ ID NO: 11.

### Claim 7

A method for screening an active ingredient of a pancreatic cancer therapeutic agent, which comprises selecting a target substance from candidate substances that lower the expression level of at least one gene selected from the group consisting of SON gene, MCM5 gene, WDR5 gene, PBK gene and CENPA gene, or that lower the bioactivity of the protein encoded by the genes.
